持田製薬の株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2023/11/14 | 3,310 | 3,310 | 3,285 | 3,285 | ±0 | ±0% | 23,200 |
2023/11/13 | 3,310 | 3,315 | 3,285 | 3,285 | -25 | -0.8% | 15,800 |
2023/11/10 | 3,270 | 3,315 | 3,265 | 3,310 | +5 | +0.2% | 21,200 |
2023/11/09 | 3,370 | 3,370 | 3,270 | 3,305 | -15 | -0.5% | 20,300 |
2023/11/08 | 3,300 | 3,330 | 3,280 | 3,320 | +20 | +0.6% | 26,700 |
2023/11/07 | 3,335 | 3,360 | 3,295 | 3,300 | -50 | -1.5% | 32,100 |
2023/11/06 | 3,395 | 3,400 | 3,310 | 3,350 | +25 | +0.8% | 49,300 |
2023/11/02 | 3,320 | 3,380 | 3,310 | 3,325 | -65 | -1.9% | 28,500 |
2023/11/01 | 3,380 | 3,395 | 3,360 | 3,390 | +80 | +2.4% | 45,100 |
2023/10/31 | 3,225 | 3,320 | 3,225 | 3,310 | +105 | +3.3% | 41,100 |
2023/10/30 | 3,260 | 3,290 | 3,190 | 3,205 | -120 | -3.6% | 42,100 |
2023/10/27 | 3,275 | 3,325 | 3,255 | 3,325 | +70 | +2.2% | 29,500 |
2023/10/26 | 3,280 | 3,320 | 3,240 | 3,255 | -45 | -1.4% | 37,000 |
2023/10/25 | 3,310 | 3,330 | 3,300 | 3,300 | -10 | -0.3% | 17,600 |
2023/10/24 | 3,310 | 3,325 | 3,245 | 3,310 | -15 | -0.5% | 21,200 |
2023/10/23 | 3,295 | 3,350 | 3,295 | 3,325 | +15 | +0.5% | 27,000 |
2023/10/20 | 3,280 | 3,330 | 3,280 | 3,310 | +20 | +0.6% | 19,400 |
2023/10/19 | 3,230 | 3,305 | 3,230 | 3,290 | +30 | +0.9% | 23,800 |
2023/10/18 | 3,295 | 3,295 | 3,215 | 3,260 | +15 | +0.5% | 24,300 |
2023/10/17 | 3,240 | 3,270 | 3,215 | 3,245 | +5 | +0.2% | 25,300 |
2023/10/16 | 3,215 | 3,275 | 3,210 | 3,240 | -30 | -0.9% | 27,800 |
2023/10/13 | 3,320 | 3,320 | 3,270 | 3,270 | -70 | -2.1% | 16,900 |
2023/10/12 | 3,365 | 3,365 | 3,315 | 3,340 | -5 | -0.1% | 12,800 |
2023/10/11 | 3,375 | 3,375 | 3,330 | 3,345 | -10 | -0.3% | 24,900 |
2023/10/10 | 3,350 | 3,370 | 3,330 | 3,355 | +35 | +1.1% | 26,700 |
2023/10/06 | 3,270 | 3,340 | 3,270 | 3,320 | +40 | +1.2% | 21,900 |
2023/10/05 | 3,205 | 3,285 | 3,205 | 3,280 | +75 | +2.3% | 32,600 |
2023/10/04 | 3,200 | 3,235 | 3,175 | 3,205 | -5 | -0.2% | 25,800 |
2023/10/03 | 3,285 | 3,290 | 3,210 | 3,210 | -75 | -2.3% | 31,900 |
2023/10/02 | 3,370 | 3,370 | 3,285 | 3,285 | -50 | -1.5% | 33,200 |
2023/09/29 | 3,365 | 3,370 | 3,320 | 3,335 | -30 | -0.9% | 26,800 |
2023/09/28 | 3,380 | 3,400 | 3,345 | 3,365 | -90 | -2.6% | 29,300 |
2023/09/27 | 3,370 | 3,455 | 3,360 | 3,455 | +80 | +2.4% | 46,300 |
2023/09/26 | 3,375 | 3,410 | 3,360 | 3,375 | -30 | -0.9% | 23,600 |
2023/09/25 | 3,355 | 3,425 | 3,355 | 3,405 | +50 | +1.5% | 32,300 |
2023/09/22 | 3,355 | 3,370 | 3,345 | 3,355 | -30 | -0.9% | 24,700 |
2023/09/21 | 3,400 | 3,430 | 3,380 | 3,385 | -10 | -0.3% | 21,100 |
2023/09/20 | 3,435 | 3,440 | 3,385 | 3,395 | -40 | -1.2% | 31,500 |
2023/09/19 | 3,420 | 3,445 | 3,410 | 3,435 | -5 | -0.1% | 25,500 |
2023/09/15 | 3,415 | 3,465 | 3,390 | 3,440 | +25 | +0.7% | 66,800 |
2023/09/14 | 3,390 | 3,425 | 3,375 | 3,415 | +10 | +0.3% | 22,400 |
2023/09/13 | 3,395 | 3,410 | 3,360 | 3,405 | +20 | +0.6% | 34,000 |
2023/09/12 | 3,340 | 3,395 | 3,340 | 3,385 | +55 | +1.7% | 27,300 |
2023/09/11 | 3,330 | 3,345 | 3,295 | 3,330 | +20 | +0.6% | 35,600 |
2023/09/08 | 3,350 | 3,370 | 3,310 | 3,310 | -70 | -2.1% | 47,800 |
2023/09/07 | 3,410 | 3,410 | 3,370 | 3,380 | -30 | -0.9% | 27,400 |
2023/09/06 | 3,415 | 3,430 | 3,395 | 3,410 | -5 | -0.1% | 21,200 |
2023/09/05 | 3,385 | 3,420 | 3,375 | 3,415 | +20 | +0.6% | 28,300 |
2023/09/04 | 3,425 | 3,425 | 3,385 | 3,395 | -20 | -0.6% | 24,100 |
2023/09/01 | 3,375 | 3,425 | 3,375 | 3,415 | +40 | +1.2% | 35,500 |
251~
300
件表示中 / 3585件
類似銘柄と比較する
現在ご覧いただいている「持田薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
持田薬 | 332,000円 | +3.0% | +27.5% | 2.41% | 21.02倍 | 0.91倍 |
|
医薬中堅。高脂血症薬、降圧薬など循環器系得意。婦人科系にも強み。消化器系育成。化粧品も |
ジーエヌアイ | 285,000円 | +52.1% | +23.3% | 0.00% | 20.23倍 | 3.88倍 |
|
中国の特発性肺線維症で高シェア、肺線維症後続薬進出。米国で人工骨も。米中に研究開発機能 |
鳥居薬 | 466,500円 | +12.0% | +28.1% | 2.57% | 25.71倍 | 1.09倍 |
|
JT傘下。柱の抗HIV薬販売権喪失後、自社製品の腎・透析、アレルゲン等の開発強化 |
ゼリア新薬 | 222,100円 | +13.6% | +29.2% | 2.07% | 11.52倍 | 1.11倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
ネクセラファーマ | 113,700円 | +197.7% | - | 0.00% | 46.47倍 | 1.48倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
市場注目の銘柄
チャート関連のコラム